**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 4220**

**Columns:** **TOPIC HIGHLIGHT**

**Michele Cicala, Professor, MD, *Series Editor***

Gastro-esophageal reflux disease: Update on inflammation and symptom perception

Altomare A *et al*. Inflammation and symptom perception in GERD

Annamaria Altomare, Michele Pier Luca Guarino, Silvia Cocca, Sara Emerenziani, Michele Cicala

**Annamaria Altomare, Michele Pier Luca Guarino, Silvia Cocca, Sara Emerenziani, Michele Cicala,** Unit of Digestive Disease, Campus Bio Medico University of Rome, 00128 Rome, Italy

**Author contributions:** All the authors contributed equally to the manuscript, drafting the article and revising it critically for important intellectual content, and approved the final version for publication.

**Correspondence to:** **Michele Cicala, MD, PhD,** Unit of Digestive Disease, Campus Bio Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy. m.cicala@unicampus.it

**Telephone**: +39-6-22541560 **Fax:** +39-6-22541520

**Received:** June 20, 2013 **Revised:** July 24, 2013

**Accepted:** August 20, 2013

**Published online:**

**Abstract**

Although gastro-esophageal reflux disease (GERD) is a common disorder in western countries with a significant impact on quality of life and healthcare costs, the mechanisms involved in the pathogenesis of symptoms remain to be fully elucidated. GERD symptoms and complications may result from a multifactorial mechanism in which acid and acid-pepsin are the important noxious factors involved; prolonged contact of the esophageal mucosa with the refluxed content, probably due to a defective anti-reflux barrier and the luminal clearance mechanisms, would appear to be responsible for macroscopically detectable injury to the esophageal squamous epithelium. Receptors on acid-sensitive nerve endings may play a role in nociception and esophageal sensitivity as suggested in animal models of chronic acid exposure. Specific cytokine and chemokine profiles would meanwhile appear to underlie the various esophageal phenotypes of GERD, explaining, in part, the genesis of esophagitis in a subset of patients. Despite these findings that show a significant production of inflammatory mediators and neurotransmitters in the pathogenesis of GERD, the relationship between the hypersensitivity and esophageal inflammation is not clear. Moreover, the large majority of GERD patients (up to 70%) do not develop esophageal erosions, a variant of the condition called non-erosive reflux disease (NERD). This summary is aimed to explore the inflammatory pathway involved in GERD pathogenesis, to better understand a possible distinction between erosive and non-erosive reflux disease patients in order to provide new therapeutic approaches.

© 2013 Baishideng. All rights reserved.

**Key words:** Gastro-esophageal reflux disease; Mucosal inflammation; Heartburn; Esophagitis; Hypersensitivity

**Core tip:** The present study was aimed to explore the mechanisms involved in the pathogenesis of gastro-esophageal reflux disease (GERD) symptoms and complications, that remain to be fully elucidated. Despite recent evidence that confirm the important production of inflammatory mediators and neurotransmitters in the pathogenesis of GERD, the interplay between the esophageal inflammation and hypersensitivity is not clear. Based on the literature and on personal experimental studies, an attempt is made herewith to summarize the evidence concerning the inflammatory pathway involved in the GERD pathogenesis, to better define a possible distinction between erosive and non-erosive reflux disease patients in order to provide new therapeutic approaches.

Altomare A, Guarino MPL, Cocca S, Emerenziani S, Cicala M. Gastro-esophageal reflux disease: Update on inflammation and symptom perception.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Gastro-esophageal reflux disease (GERD) is a common disorder in Western countries with 10%-30% of the individuals affected every week by symptoms which have a significant impact on quality of life and healthcare costs[1-3]. In GERD, the mechanisms involved in the pathogenesis of heartburn and chest pain remain to be completely elucidated, however acid and pepsin can induce macroscopically detectable injury to the esophageal squamous epithelium[4]. Injured or inflamed tissues are known to release inflammatory mediators that can be detected by the immune system. Moreover, in response to these chemical insults, endothelial cells produce adhesion molecules, which have been shown to recruit and activate leukocytes, thus mediating inflammatory conditions.[5] In an experimental model of reflux esophagitis and in patients affected by GERD, some of the mediators that are considered to be critical in the etiology of esophagitis, are classic inflammatory products, such as prostanoids and reactive oxygen species (ROS)[6,7]. Several studies have also suggested that the mucosal immune and inflammatory responses, characterized by specific cytokine and chemokine profiles, may underlie the various esophageal phenotypes of GERD[8-11]. Indeed, the large majority of GERD patients (up to 70%) do not develop esophageal erosions, a variant of the condition called non-erosive reflux disease (NERD)[12,13].Although several studies report the progression of NERD to erosive esophagitis (erosive reflux disease, ERD), structural and functional characteristics differentiate these two important GERD groups: NERD patients usually have a normal lower esophageal sphincter resting pressure, minimal esophageal body motility abnormalities, low esophageal acid exposure profile and minimal night-time esophageal acid exposure[14,15].The symptom response, in NERD patients, to acid suppressive therapy is lower than that in patients with ERD[14].In fact in these patients, esophageal visceral hypersensitivity, sustained esophageal contractions or impaired tissue resistance have been identified as possible mechanisms responsible for reflux symptoms and PPI resistance[16-18].

This brief summary is aimed at focusing on the inflammatory pathway involved in the pathogenesis of GERD, in order to better understand the distinction between ERD and NERD patients and thus to provide better therapeutic approaches.

**DAMAGE INDUCED BY REFLUXATE**

GERD is a complex disorder with the potential for developing esophagitis, esophageal strictures and Barrett's esophagus[2]. GERD symptoms and complications may result from a multifactorial mechanism in which acid and acid-pepsin are the important noxious factors involved; prolonged contact of the esophageal mucosa with the refluxed content, possibly due to a defective anti-reflux barrier and the luminal clearance mechanisms, would appear to be responsible for the morphological changes in the esophageal epithelium of GERD patients[19,20].

A well studied ultra-structural alteration, i.e., dilated intercellular spaces (DIS), demonstrated both in ERD and NERD patients[21,22], could explain the genesis of symptoms triggered by the activation of intra-mucosal chemo-sensitive nociceptors and, at the same time, the inflammatory cascade generated by luminal acid diffusing into the tissue. In conditions not associated with severe inflammation, it is not clear how, in the presence of these symptoms, an injurious process initiating in the normal mucosa may lead to macroscopic injuries in a subset of patients (30%-40%), namely the ERD group.

The increased paracellular permeability, associated with the presence of DIS, and the resulting breakdown in the epithelial barrier, do not necessarily result only from excessive acid exposure, as suggested by the normal acid contact time at pH-monitoring in NERD patients, in which the symptoms are generated in the absence of esophageal epithelial erosions[23]. At the same time, the esophageal mucosa would appear to play a pivotal role in the development of esophageal inflammation and pain. Unlike intestinal inflammation, in which the role of the mucosa has been studied, as far as concerns the esophagus, it has only recently been suggested that gastric juice reflux does not directly damage the esophageal mucosa, but instead stimulates the esophageal epithelial cells to secrete chemokines that attract and activate the immune cells, causing damage to the esophageal squamous epithelial cells[23]. Microscopic inflammation, characterized by neutrophilic and eosinophilic infiltration of the esophageal mucosa and submucosa, is observed more frequently in ERD than in NERD patients[24-26].

Therefore the different esophageal phenotypes of GERD could possibly be the presence of various inflammatory mediators responsible for mucosal immune responses in these groups of patients[8, 27-28].

In a recent investigation we observed that levels of cytokines, such as interleukin-8 (IL-8) and platelet activating factor (PAF), are significantly higher in the esophageal mucosa of ERD patients compared to that in the NERD group, in whom the expression of these inflammatory mediators is comparable to those of controls[11]. The acid-induced production of IL-8 and other inflammatory mediators, by the esophageal mucosa, have been shown to promote migration and activation of peripheral blood leukocytes[29]. These findings would corroborate the hypothesis that a cytokine-mediated mechanism, rather than a direct effect of gastroesophageal reflux, is responsible for the mucosal injury in the ERD subgroup.

Albeit, growing evidence shows that NERD patients are characterized by an enhanced esophageal sensitivity to chemical and mechanical stimuli due to enhanced excitability of visceral sensory neurons, possibly associated with over expression of acid-sensing receptors in the epithelial layer and in the afferent fibers of the *lamina propria*[30,31].

In particular, the transient receptor potential channel vanilloid subfamily member-1 (TRPV1) is over-expressed in the esophageal mucosa of ERD and NERD patients, compared to healthy controls, perhaps thus explaining the similar severity of reflux symptoms in both groups regardless of the presence or absence of inflammation and erosions[25].

**INFLAMMATORY MEDIATORS AND GERD PATHOGENESIS**

It is well known that the mucosa of GERD patients produces significantly larger amounts of various cytokines compared to that of healthy controls[8-10,26,28,32]. These inflammatory mediators are known to activate immune cell recruitment and migration, and may be involved in the pathophysiology of GERD (Table 1).

IL-8, one of the most important neutrophil chemoattractants[33] is over-expressed in the mucosa of GERD patients[8-10]. Moreover, increased IL-8 levels in the esophageal mucosa of these patients have been reported to correlate with the endoscopic and histological severity of the disease[8-10] and moreover to decrease following PPIs[34] and following anti-reflux surgery[35], possibly indicating a role of this chemokine in the mucosal damage. Acid-induced production of IL-8 and PAF by the esophageal mucosa promotes the migration of peripheral blood leukocytes. PAF also induces the production of hydrogen peroxide (H2O2) by peripheral blood leukocytes[29].

In a previous study, we have shown that acid-induced inflammation of the esophagus begins with activation of the TRPV1 receptors in the mucosa and synthesis of PAF by the epithelial cells[36]. Furthermore the production of the sensory neurotransmitters calcitonin-gene related peptide (CGRP) and substance P by sensory neurons located in the esophageal mucosal layer has been reported[29].

PAF diffuses from the mucosal layer stimulating the production of H2O2 in leukocytes and the production of IL-6 in the circular muscle, where IL-6 causes production of additional H2O2 through activation of NADPH oxidases present in the circular muscle layer[37]. In turn, H2O2 triggers the formation of IL-1beta that may induce the production of PAF in the muscle, probably supporting a self-sustaining cycle of inflammatory mediator production. Indeed, in an animal model of chronic esophagitis, a significantly increased expression of other inflammatory mediators, among which IL-1beta, tumor necrosis factor-alfa (TNF-alfa), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1alfa (MIP-1α) and eotaxins, was detected in esophageal lesions compared with the normal esophagus[11,38]. In agreement with these previous reports, we recently confirmed, in biopsies from ERD patients, a significant increase in the expression of IL-8, PAF and several chemokines, compared to controls[25]. Interestingly, unlike ERD patients, the esophageal mucosa of NERD patients did not exhibit an enhanced expression of various inflammatory mediators, or significant presence of neutrophils and eosinophils in the mucosa, comparable to asymptomatic controls[11,23,24].

This hypothesis is therefore supported by a multicenter, randomized, controlled trial including 514 patients affected by GERD[26]. The study revealed that “microscopic esophagitis” (dilatation of intercellular spaces, papillar elongation and basal cell hyperplasia), was found in more than 90% of ERD patients but in only approximately 2/3 of NERD patients[26], with a significant immune cells infiltrate only in the ERD group.

These findingswould indicate a key role of several soluble mediators acting as powerful inflammatory activators, contributing to the induction of esophagitis. The observation that CGRP and substance P are generated by different mechanisms and that the sensation of heartburn and inflammation are probably mediated by two different pathways, would further explain the presence of recurrent and severe symptoms irrespective of mucosal injury.

**VISCERAL HYPERSENSITIVITY AND REFLUX PERCEPTIONS IN GERD PATIENTS**

The pathogenesis of heartburn and of acid regurgitation still remains to be fully elucidated, particularly in the numerous NERD patients, in whom the 24-hour pH-test findings may be within the normal range[39] and indeed an enhanced sensitivity to reflux would appear to be strongly associated with the failure of proton pump inhibitor treatment[40].

Although gastric acid plays a pivotal role in the pathogenesis of GERD, other stimuli have been suggested to be involved in the pathogenesis of typical symptoms. In patients with GERD, reflux may result in direct activation of pain receptors, and this may be enhanced by greater acid diffusion through the esophageal epithelium caused by impaired mucosal barrier function[19]. Furthermore, activation of pain receptors may occur following reflux-induced distention of the esophagus. Enhanced esophageal sensitivity to these stimuli may be due to up-regulation of peripheral pain receptors and central sensitization of spinal neurons[19].

Little is known about acid-sensitive nerves. Receptors on acid-sensitive nerve endings may play a role in nociception and esophageal sensitivity as suggested in animal models following chronic acid exposure, and include the anion-sensing ion channel (ASIC), TRPV1 and ionotrophic purinergic (P2X and P2Y) receptors[4].

The recently demonstrated presence of acid-sensitive TRPV1 receptors in sensory nerve fibers and in epithelial cells of the esophageal mucosa[41], provides an interesting mechanism to better understand the onset of neuromodulation and symptoms generation in GERD. TRPV1 activation in primary afferent neurons evokes the sensation of burning pain and may induce neurogenic inflammation following the release of substance P and CGRP[36].

On the other hand, growing evidence, in animal models during chronic acid exposure, supports the involvement of purinergic receptors in nociception and hypersensitivity[38,39].The purinergic receptors are involved in several cell functions and may be activated by purine nucleotides as ligands[42].

Based on pharmacological properties and molecular characteristics, two distinct classes of purinergic receptors with preferential response to adenosine 5’-triphosphate (ATP), as well as other single nucleotides, have been identified, namely the family of ligand-gated cation channel P2X receptors and the G protein-coupled P2Y receptors.

It is well known that P2X and P2Y receptors play an important role in signaling visceral pain[19,39,42].A working hypothesis of purine-mediated mechano-sensory transduction has been suggested[19,39]: ATP released from the epithelial cell lining of the gastrointestinal (GI) tract, bladder, and ureter might activate P2X receptors present on the sub-epithelial nerve plexus and the signal is transmitted via the spinal cord to the brain.

To date, a limited number of studies have been performed on changes in purinergic signaling in GI disorders. Extra-cellular nucleotides and their receptors have been implicated in the pathogenesis of various pathological conditions in the gut: indeed it has been demonstrated that adenosine increases vagal afferent sensitization in the esophagus and is able to activate a different type of nociceptive nerve terminals in this tissue[43]. Acid has been shown to sensitize P2X receptors to ATP and an acid-induced up-regulation and activation of P2X receptors has been confirmed in animal models of esophagitis[44,45].

However, the role of purinergic receptors in patients with GERD remains to be fully elucidated. In a recent investigation we studied a signaling pathway possibly responsible for esophageal nociception that involves ATP and purinoceptors. In an experimental model of acid-induced activation of the esophageal mucosal nociceptors, we observed that acid exposure causes activation of TRPV1 receptors on the esophageal epithelial cells triggering production of ATP that acts on peripheral nerve terminals inducing the production of neurotransmitters[46].Thus, the selective presence of purinergic receptors on esophageal epithelial cells was demonstrated, suggesting a direct effect of the acid on the epithelium and a possible autocrine effect of ATP on these cells[19]. In fact, P2X4, P2X5 and P2Y14 receptors are expressed in the esophageal epithelial cells, and indeed are higher than all the other purinergic receptors[46].P2Y receptors appear to be involved more in esophageal motility. Lecea et al[47] recently reported that purinoceptors are involved in human lower esophageal sphincter (LES) relaxation, mediated by neural nitric oxide and partially by P2Y receptors; blockade of P2Y receptors reduced the amplitude of contractions, without affecting the latency.Farrè *et al*[48] had previously demonstrated, in animals, that LES relaxation, induced by stimulation of the inhibitory motoneurons of the mioenteric plexus, was mediated by neural nitric oxide with a minor contribution of purines, acting by way of P2Y and P2X receptors.

**CONCLUSION**

Inflammatory processes in the esophageal mucosa appear to be involved not only in the development of erosive disease but, also, in the early and important phases leading to hypersensitivity to intra-luminal stimuli.

Despite considerable evidence reconfirming the important production of inflammatory mediators and/or neurotransmitters in the pathogenesis of GERD, the interplay between the hypersensitivity and esophageal inflammation is still not clear. Moreover, in pathogenesis of GERD and in the generation of symptoms, receptors on acid-sensitive nerve endings may play a significant role. Further studies are warranted to better understand the signaling pathway involved in the genesis of reflux symptoms and inflammation in order to identify and establish new therapeutic approaches.

**ACKNOWLEDGMENTS**

Authors are grateful to Mrs. Marian Shields for help with the English manuscript.

**REFERENCES**

1 **Dent J**, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut* 2005; **54**: 710-717 [PMID: 15831922 DOI: 10.1136/gut.2004.051821]

2 **Locke GR**, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. *Gastroenterology* 1997; **112**: 1448-1456 [PMID: 9136821 DOI: 10.1016/S0016-5085(97)70025-8]

3 **Camilleri M**, Dubois D, Coulie B, Jones M, Kahrilas PJ, Rentz AM, Sonnenberg A, Stanghellini V, Stewart WF, Tack J, Talley NJ, Whitehead W, Revicki DA. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. *Clin Gastroenterol Hepatol* 2005; **3**: 543-552 [PMID: 15952096 DOI: 10.1016/S1542-3565(05)00153-9]

4 **Barlow WJ**, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. *Gastroenterology* 2005; **128**: 771-778 [PMID: 15765412 DOI: 10.1053/j.gastro.2004.08.014]

5 **Kelly M**, Hwang JM, Kubes P. Modulating leukocyte recruitment in inflammation. *J Allergy Clin Immunol* 2007; **120**: 3-10 [PMID: 17559914 DOI: 10.1016/j.jaci.2007.05.017]

6 **Jiménez P**, Piazuelo E, Sánchez MT, Ortego J, Soteras F, Lanas A. Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. *World J Gastroenterol* 2005; **11**: 2697-2703 [PMID: 15884106 DOI: 10.1016/S0016-5085(03)82065-6]

7 **Oh TY**, Lee JS, Ahn BO, Cho H, Kim WB, Kim YB, Surh YJ, Cho SW, Hahm KB. Oxidative damages are critical in pathogenesis of reflux esophagitis: implication of antioxidants in its treatment. *Free Radic Biol Med* 2001; **30**: 905-915 [PMID: 11295533 DOI: 10.1016/S0891-5849(01)00472-5]

8 **Fitzgerald RC**, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. *Gut* 2002; **50**: 451-459 [PMID: 11889061 DOI: 10.1136/gut.50.4.451]

9 **Isomoto H**, Wang A, Mizuta Y, Akazawa Y, Ohba K, Omagari K, Miyazaki M, Murase K, Hayashi T, Inoue K, Murata I, Kohno S. Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis. *Am J Gastroenterol* 2003; **98**: 551-556 [PMID: 12650786 DOI: 10.1016/S0002-9270(02)06025-2]

10 **Yoshida N**, Uchiyama K, Kuroda M, Sakuma K, Kokura S, Ichikawa H, Naito Y, Takemura T, Yoshikawa T, Okanoue T. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. *Scand J Gastroenterol* 2004; **39**: 816-822 [PMID: 15513378 DOI: 10.1080/00365520410006729]

11 **Altomare A**, Ma J, Guarino MP, Cheng L, Rieder F, Ribolsi M, Fiocchi C, Biancani P, Harnett K, Cicala M. Platelet-activating factor and distinct chemokines are elevated in mucosal biopsies of erosive compared with non-erosive reflux disease patients and controls. *Neurogastroenterol Motil* 2012; **24**: 943-e463 [PMID: 22734465 DOI: 10.1111/j.1365-2982.2012.01963.x]

12 **Fass R**, Ofman JJ. Gastroesophageal reflux disease--should we adopt a new conceptual framework? *Am J Gastroenterol* 2002; **97**: 1901-1909 [PMID: 12190152 DOI: 10.1016/S0002-9270(02)04269-7]

13 **Armstrong D**. Endoscopic evaluation of gastro-esophageal reflux disease. *Yale J Biol Med* 1999; **72**: 93-100 [PMID: 10780570]

14 **Fass R**. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. *J Clin Gastroenterol* 2007; **41**: 131-137 [PMID: 17245209 DOI: 10.1097/01.mcg.0000225631.07039.6d]

15 **Dent J**, Brun J, Fendrick A, Fennerty M, Janssens J, Kahrilas P, Lauritsen K, Reynolds J, Shaw M, Talley N. An evidence-based appraisal of reflux disease management. The Genval workshop report. Gut 1999; **44**: 1-16 [DOI: 10.1136/gut.44.2008.S1]

16 **Orlando RC**. The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure. *Am J Gastroenterol* 1997; **92**: 3S-5S; discussion 5S-7S [PMID: 9127620]

17 **Trimble KC**, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. *Gut* 1995; **37**: 7-12 [PMID: 7672684 DOI: 10.1136/gut.37.1.7]

18 **Pehlivanov N**, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. *Am J Physiol Gastrointest Liver Physiol* 2001; **281**: G743-G751 [PMID: 11518687 DOI: 10/2001; ]

19 **Bredenoord AJ**. Mechanisms of reflux perception in gastroesophageal reflux disease: a review. *Am J Gastroenterol* 2012; **107**: 8-15 [PMID: 22218024 DOI: 10.1038/ajg.2011.286]

20 **Zaika E**, Bhardwaj V, Wei J, Washington MK, Souza R, El-Rifai W, Zaika A. Proinflammatory cytokines and bile acids upregulate ΔNp73 protein, an inhibitor of p53 and p73 tumor suppressors. *PLoS One* 2013; **8**: e64306 [PMID: 23717592 DOI: 10.1371/journal.pone.0064306]

21 **Tobey NA**, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces: a morphological feature of acid reflux--damaged human esophageal epithelium. *Gastroenterology* 1996; **111**: 1200-1205 [PMID: 8898633 DOI: 10.1053/gast.1996.v111.pm8898633]

22 **Caviglia R**, Ribolsi M, Maggiano N, Gabbrielli AM, Emerenziani S, Guarino MP, Carotti S, Habib FI, Rabitti C, Cicala M. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. *Am J Gastroenterol* 2005; **100**: 543-548 [PMID: 15743349 DOI: 10.1111/j.1572-0241.2005.40978.x]

23 **Tutuian R**, Castell DO. Review article: complete gastro-oesophageal reflux monitoring - combined pH and impedance. *Aliment Pharmacol Ther* 2006; **24 Suppl 2**: 27-37 [PMID: 16939430 DOI: 10.1111/j.1365-2036.2006.03039.x]

24 **Souza RF**, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. *Gastroenterology* 2009; **137**: 1776-1784 [PMID: 19660463 DOI: 10.1053/j.gastro.2009.07.055]

25 **Guarino MP**, Cheng L, Ma J, Harnett K, Biancani P, Altomare A, Panzera F, Behar J, Cicala M. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. *Neurogastroenterol Motil* 2010; **22**: 746-51, e219 [PMID: 20456759 DOI: 10.1111/j.1365-2982.2010.01514.x]

26 **Isomoto H**, Saenko VA, Kanazawa Y, Nishi Y, Ohtsuru A, Inoue K, Akazawa Y, Takeshima F, Omagari K, Miyazaki M, Mizuta Y, Murata I, Yamashita S, Kohno S. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease. *Am J Gastroenterol* 2004; **99**: 589-597 [PMID: 15089887 DOI: 10.1111/j.1572-0241.2004.04110.x]

27 **Fiocca R**, Mastracci L, Engström C, Attwood S, Ell C, Galmiche JP, Hatlebakk J, Junghard O, Lind T, Lundell L. Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. *Am J Gastroenterol* 2010; **105**: 1015-1023 [PMID: 19904246 DOI: 10.1038/ajg.2009.631]

28 **Mönkemüller K**, Wex T, Kuester D, Fry LC, Peitz U, Beyer M, Roessner A, Malfertheiner P. Interleukin-1beta and interleukin-8 expression correlate with the histomorphological changes in esophageal mucosa of patients with erosive and non-erosive reflux disease. *Digestion* 2009; **79**: 186-195 [PMID: 19342859 DOI: 10.1159/000211714]

29 **Ma J**, Altomare A, de la Monte S, Tong M, Rieder F, Fiocchi C, Behar J, Shindou H, Biancani P, Harnett KM. HCl-induced inflammatory mediators in esophageal mucosa increase migration and production of H2O2 by peripheral blood leukocytes. *Am J Physiol Gastrointest Liver Physiol* 2010; **299**: G791-G798 [PMID: 20616304 DOI: 10.1152/ajpgi.00160.2010]

30 **Martinez SD**, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)--acid reflux and symptom patterns. *Aliment Pharmacol Ther* 2003; **17**: 537-545 [PMID: 12622762 DOI: 10.1046/j.1365-2036.2003.01423.x]

31 **Bhat YM**, Bielefeldt K. Capsaicin receptor (TRPV1) and non-erosive reflux disease. *Eur J Gastroenterol Hepatol* 2006; **18**: 263-270 [PMID: 16462539 DOI: 10.1097/00042737-200603000-00006]

32 **Rieder F**, Cheng L, Harnett KM, Chak A, Cooper GS, Isenberg G, Ray M, Katz JA, Catanzaro A, O'Shea R, Post AB, Wong R, Sivak MV, McCormick T, Phillips M, West GA, Willis JE, Biancani P, Fiocchi C. Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities. *Gastroenterology* 2007; **132**: 154-165 [PMID: 17241868 DOI: 10.1053/j.gastro.2006.10.009]

33 **Harada A**, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. *J Leukoc Biol* 1994; **56**: 559-564 [PMID: 7964163 DOI: 10.1186/ar1917]

34 **Isomoto H**, Nishi Y, Kanazawa Y, Shikuwa S, Mizuta Y, Inoue K, Kohno S. Immune and Inflammatory Responses in GERD and Lansoprazole. *J Clin Biochem Nutr* 2007; **41**: 84-91 [PMID: 18193101 DOI: 10.3164/jcbn.2007012]

35 **Oh DS**, DeMeester SR, Vallbohmer D, Mori R, Kuramochi H, Hagen JA, Lipham J, Danenberg KD, Danenberg PV, Chandrasoma P, DeMeester TR. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. *Arch Surg* 2007; **142**: 554-59; discussion 554-59; [PMID: 17576892 DOI: 10.1001/archsurg.142.6.554]

36 **Ma J**, Altomare A, Guarino M, Cicala M, Rieder F, Fiocchi C, Li D, Cao W, Behar J, Biancani P, Harnett KM. HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. *Am J Physiol Gastrointest Liver Physiol* 2012; **303**: G635-G645 [PMID: 22790593 DOI: 10.1152/ajpgi.00097.2012]

37 **Cheng L**, Cao W, Fiocchi C, Behar J, Biancani P, Harnett KM. HCl-induced inflammatory mediators in cat esophageal mucosa and inflammatory mediators in esophageal circular muscle in an in vitro model of esophagitis. *Am J Physiol Gastrointest Liver Physiol* 2006; **290**: G1307-G1317 [PMID: 16439466 DOI: 10.1152/ajpgi.90386.2008]

38 **Hamaguchi M**, Fujiwara Y, Takashima T, Hayakawa T, Sasaki E, Shiba M, Watanabe T, Tominaga K, Oshitani N, Matsumoto T, Higuchi K, Arakawa T. Increased expression of cytokines and adhesion molecules in rat chronic esophagitis. *Digestion* 2003; **68**: 189-197 [PMID: 14691346 DOI: 75698]

39 **Knowles CH**, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. *Gut* 2008; **57**: 674-683 [PMID: 18079285 DOI: 10.1136/gut.2007.127886]

40 **Ribolsi M**, Emerenziani S, Petitti T, Addarii MC, Balestrieri P, Cicala M. Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responders to proton pump inhibitors. *Dig Liver Dis* 2012; **44**: 549-554 [PMID: 22366345 DOI: 10.1016/j.dld.2012.01.007]

41 **Matthews PJ**, Aziz Q, Facer P, Davis JB, Thompson DG, Anand P. Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. *Eur J Gastroenterol Hepatol* 2004; **16**: 897-902 [PMID: 15316415 DOI: 10.1097/00042737-200409000-00014]

42 **Birder LA**. Urothelial signaling. *Auton Neurosci* 2010; **153**: 33-40 [PMID: 19666243 DOI: 10.1016/j.autneu.2009.07.005]

43 **Page AJ**, O'Donnell TA, Blackshaw LA. P2X purinoceptor-induced sensitization of ferret vagal mechanoreceptors in oesophageal inflammation. *J Physiol* 2000; **523** Pt 2: 403-411 [PMID: 10699084 DOI: 10.1111/j.1469-7793.2000.00403.x]

44 **North RA**. Molecular physiology of P2X receptors. *Physiol Rev* 2002; **82**: 1013-1067 [PMID: 12270951]

45 **Bertrand PP**. ATP and sensory transduction in the enteric nervous system. *Neuroscientist* 2003; **9**: 243-260 [PMID: 12934708 DOI: 10.1177/1073858403253768]

46 **Ma J**, Altomare A, Rieder F, Behar J, Biancani P, Harnett KM. ATP: a mediator for HCl-induced TRPV1 activation in esophageal mucosa. *Am J Physiol Gastrointest Liver Physiol* 2011; **301**: G1075-G1082 [PMID: 21960521 DOI: 0.1152/ajpgi.00336.2011]

47 **Lecea B**, Gallego D, Farré R, Opazo A, Aulí M, Jiménez M, Clavé P. Regional functional specialization and inhibitory nitrergic and nonnitrergic coneurotransmission in the human esophagus. *Am J Physiol Gastrointest Liver Physiol* 2011; **300**: G782-G794 [PMID: 21330444 DOI: 10.1152/ajpgi.00514.2009]

48 **Farré R**, Aulí M, Lecea B, Martínez E, Clavé P. Pharmacologic characterization of intrinsic mechanisms controlling tone and relaxation of porcine lower esophageal sphincter. *J Pharmacol Exp Ther* 2006; **316**: 1238-1248 [PMID: 16303917 DOI: 10.1124/jpet.105.094482]

**P-Reviewer** Tiberio GAM **S-Editor** Wen LL  **L-Editor**  **E-Editor**

**Table 1 Cytokines and Chemokines involved in the pathophysiology of gastroesophageal reflux disease**

|  |  |  |  |
| --- | --- | --- | --- |
| **Patients** |  | **Cytokines** | **Chemokines** |
| GERD |  | IL-6[8,23], and IL-8[8-11,23,25,29], IL-1β[23,28,32,38], INF-γ[8], TNF-α[20,38] |  |
|  |  |  |
|  |  |  |
|  | ERD | IL-6[32,37], IL-8[8-11,25,28], IL-1β[28,32,37,38] | PAF[11,36,37],MCP-1[9-11,36,38],RANTES[9,36],MIP1-α[11,36,38], Eotaxin-1,Eotaxin-2 and Eotaxin-3[11,36], CINC-2α[38],and ICAM-1[38] |
|  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  | NERD | IL-8[10,25,28], IL-1β[28] |  |
| Barrett's esophagus |  | IL-8[8], IL-4[8],TNF-α[34],IL-6[34],IL-8[35] |  |
|  |  |

GERD: Gastroesophageal reflux disease; ERD: Erosive reflux disease; NERD: Non erosive reflux disease; IL-6: Interleukin-6; IL-8: Interleukin-8; IL-1β: Interleukin-1beta; INF-γ: Interferon-gamma; TNF-α: Tumor necrosis factor-alfa; PAF: Platelet-activating factor; MCP-1: Monocyte chemoattractant protein; MIP-1α: Macrophage inflammatory protein-1alfa; CINC-2α: Cytokine-induced neutrophil chemoattractant-2alfa; ICAM-1: Intercellular Adhesion Molecule-1.